Source-grounded facts extracted from Aspire Biopharma Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aspire Biopharma Holdings, Inc. entered into Non-Redemption Agreement and Assignment of Economic Interest with unaffiliated third party (effective 2023-04-27).
“On April 27, 2023, PowerUp Sponsor LLC (the “ Sponsor ”), the sponsor of PowerUp Acquisition Corp. (the “ Company ”), and the Company, entered into a Non-Redemption Agreement and Assignment of Economic Interest (the “ Non-Redemption Agreement ”) with an unaffiliated third party”
Kyle Campbell was appointed as Class III director at Aspire Biopharma Holdings, Inc..
“Effective May 16, 2022, the board of directors (the “Board”) of PowerUp Acquisition Corp., a Cayman Islands exempted company (the “Company”), appointed Kyle Campbell, as a Class III director of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.